Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Clinical trial NCT02978222 · TERMINATED
Trial details
- NCT number
- NCT02978222
- Sponsor
- Marker Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-20
- Primary completion
- 2020-01-15
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.